Rajesh Karan - Novartis Pharma AG | 人才画像

基本信息

浏览量：2

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 17 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Biologically Defined Neuronal Synuclein Disease As a Tool to Advance Drug Development

Gennaro Pagano,Tien Dam,Geoffrey A Kerchner,Wendy R Galpern, Milton Biagioni,Rajesh Karan,Danna Jennings,M Judith Peterschmitt,Tania Nikolcheva,Patrik Brundin

NPJ Parkinson's diseaseno. 1 (2024): 235-235

引用0浏览0WOSNATURE引用

ORCHESTRA: A GLOBAL, RANDOMIZED, PHASE II STUDY OF HIGH- AND LOW-DOSE MINZASOLMIN (UCB0599), A SMALL MOLECULE ASYN MISFOLDING INHIBITOR, IN EARLY-STAGE PARKINSON'S DISEASE

Amit Khanna,Rajesh Karan, Zahid Ali,Ralph P. Maguire,Astrid Schmidt,Coralie Domange,Peter Basile,Maria Key Prato,Stan Carson

MOVEMENT DISORDERS（2023）

引用0浏览0引用

Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis

Heinz Wiendl,Laura Airas,Tanuja Chitnis,Mitzi Williams,Jin Nakahara,Robert Bermel,Brett Loop, Gisele El Hayek,Alit Bhatt,Brian Hunter, Ying Zhang,Rajesh Karan,Roman Willi,Bernd Kieseier,Xavier Montalban

Multiple Sclerosis and Related Disorders（2023）

引用0浏览0引用

The Bioequivalence Between Valsartan Oral Solution and Suspension Formulations Developed for Pediatric Use

Rama Sivasubramanian,Gangadhar Sunkara,Rajesh Karan,Wei Zhou,Yiming Zhang,Ramachandra Sangana

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT（2022）

引用1浏览0WOS引用

Phase 3 REMODEL I/II Trials: Effectiveness, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis (P7-4.003)

Heinz Wiendl,Laura Airas,Tanuja Chitnis,Mitzi Williams,Jin Nakahara,Robert Bermel,Allison Mann,Marina Ziehn,Alit Bhatt,Brian Hunter, Ying Zhang,Rajesh Karan,Roman Willi,Bernd C. Kieseier,Xavier Montalban

Neurologyno. 18_supplement (2022)

引用0浏览0引用

Effect of Fingolimod on Health-Related Quality of Life in Paediatric Patients with Multiple Sclerosis: Results from the Phase 3 PARADIGMS Study

Lauren Krupp,Brenda Banwell,Tanuja Chitnis,Kumaran Deiva,Jutta Gaertner,Angelo Ghezzi,Peter Huppke,Emmanuelle Waubant,Virginia DeLasHeras,Amin Azmon,Rajesh Karan

BMJ Neurology Openno. 1 (2022): e000215-e000215

引用8浏览0WOS引用

Real-world Utilisation of the Rivastigmine Transdermal Patches Accom-panying the Use of Risk Minimisation Tools in Patients with Dementia

Fritjof Reinhardt,Nikolaos Scarmeas,Rajesh Karan,Uday K. Veldandi, Sunil Modali, Krishna Duvvuri,Rashid K. Pathan

CURRENT ALZHEIMER RESEARCH（2021）

引用2浏览0WOS引用

Efficacy and Safety of 2 Fingolimod Doses Vs Glatiramer Acetate for the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis A Randomized Clinical Trial

Bruce A. C. Cree,Myla D. Goldman,John R. Corboy,Barry A. Singer,Edward J. Fox,Douglas L. Arnold,Corey Ford,Bianca Weinstock-Guttman,Amit Bar-Or,Susanne Mientus,Daniel Sienkiewicz,Ying Zhang,Rajesh Karan,Nadia Tenenbaum

JAMA Neurology（2020）

引用21浏览0WOS引用

Efficacy and Safety of Fingolimod 0.5 Mg and 0.25 Mg Versus Glatiramer Acetate 20 Mg in Patients with Relapsing-Remitting Multiple Sclerosis – ASSESS Study Group (S56.009)

Bruce Cree,Myla Goldman,John Corboy,Barry Singer,Edward Fox,Douglas Arnold,Corey Ford,Bianca Weinstock-Guttman,Amit Bar-Or,Susanne Mientus,Daniel Sienkiewicz, Ying Zhang,Rajesh Karan,Nadia Tenenbaum

Neurologyno. 15_supplement (2019)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn